As shown in Figure 4A, VD3 treatment did not affect RARRES2 plasma concentration in control rats, while in PCOS rats, we noted higher levels of RARRES2 (p < 0.05). This evidence concerns the gene RARRES2 and polycystic ovary syndrome.